IRVINE, Calif., Nov. 24, 2009 (GLOBE NEWSWIRE) -- According to several recent reports, the vaccine marketplace will show big gains through 2012 as it emerges as one of the most lucrative sectors in the global pharmaceutical industry.
This bodes well for innovative companies such as TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of cell-based immunotherapeutics and vaccines in the areas of oncology and infectious disease.
With CAGR projected by some at over 13% through 2012, the vaccine therapy industry may well emerge as the fastest growing pharmaceutical segment, with the two largest markets being the U.S. and Europe. And vaccines treating various forms of cancer currently represent one of the most lucrative areas for vaccine makers.
View a report on TapImmune at: http://www.qualitystocks.net/clients.php?clientid=tpiv#head
TapImmune is enjoying a surge in interest by the investment community and potential development partners. The biotech market has gained tremendous momentum in both the cancer vaccine and infectious disease areas driven by a pandemic threat of many diseases including a significant outbreak of H1N1 ("Swine Flu") and the recent success of Dendreon's Provenge Phase III prostate cancer clinical trial.
TapImmune's lead product candidate, the AdhTAP vaccine enhancer is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. As a vaccine, TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz is property of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities but is for information purposes only and shouldn't be used as a basis for any investment decision. MP isn't an investment advisor, analyst or licensed broker/dealer and this report isn't investment advice. MP has been paid fifteen hundred dollars by Dream Team Group for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies. MP's analyst, J. Knepp, holds CRD#2849651. To be featured in our publications please call the number below.